Measles Immunity Repurposed: mRNA-LNP Delivery of Hemagglutinin Protein Enhances Antitumor CD8⁺ T Cell Response

A new study reveals that utilizing pre-existing immunity to measles through mRNA-lipid nanoparticle (LNP) delivery of the measles hemagglutinin (HA) protein can significantly enhance antitumor CD8⁺ T cell responses. Researchers found that this approach effectively redirects the immune system to target tumors, offering a novel strategy for cancer immunotherapy.

The study demonstrated that mRNA-LNP-mediated expression of measles HA boosts the activation and proliferation of CD8⁺ T cells specific to measles. This activation occurs because a large portion of the population already has immunity to measles. When the measles HA protein is expressed, the immune system recognizes it and mounts a robust response. Furthermore, researchers engineered the measles HA mRNA-LNP to target tumor cells, leading to a concentrated immune attack on the cancer. The results indicated a marked increase in the infiltration of CD8⁺ T cells into the tumor microenvironment, resulting in enhanced tumor cell killing and improved overall survival in preclinical models. This strategy holds promise for individuals who have previously been exposed to measles or vaccinated against it, potentially offering a more effective and targeted approach to cancer treatment.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 4, 2026

Author

GOAI